107 related articles for article (PubMed ID: 11856478)
1. Overexpression of urokinase-type plasminogen activator in human gastric cancer cell line (AGS) induces tumorigenicity in severe combined immunodeficient mice.
Choi YK; Yoon BI; Kook YH; Won YS; Kim JH; Lee CH; Hyun BH; Oh GT; Sipley J; Kim DY
Jpn J Cancer Res; 2002 Feb; 93(2):151-6. PubMed ID: 11856478
[TBL] [Abstract][Full Text] [Related]
2. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system.
Lee DH; Yang Y; Lee SJ; Kim KY; Koo TH; Shin SM; Song KS; Lee YH; Kim YJ; Lee JJ; Choi I; Lee JH
Cancer Res; 2003 Aug; 63(15):4648-55. PubMed ID: 12907645
[TBL] [Abstract][Full Text] [Related]
3. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
4. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
[TBL] [Abstract][Full Text] [Related]
5. The effects of cyclooxygenase2-prostaglandinE2 pathway on Helicobacter pylori-induced urokinase-type plasminogen activator system in the gastric cancer cells.
Iwamoto J; Mizokami Y; Takahashi K; Matsuoka T; Matsuzaki Y
Helicobacter; 2008 Jun; 13(3):174-82. PubMed ID: 18466392
[TBL] [Abstract][Full Text] [Related]
6. [uPA expression of gastric cancer cell lines and its correlation with peritoneal seeding].
Ding YC; Zhu ZG; Liu BY; Ji YB; Chen XH; Zhang Y; Yu YY; Lin YZ
Zhonghua Zhong Liu Za Zhi; 2005 Jan; 27(1):13-5. PubMed ID: 15771790
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer.
Kaneko T; Konno H; Baba M; Tanaka T; Nakamura S
Cancer Sci; 2003 Jan; 94(1):43-9. PubMed ID: 12708473
[TBL] [Abstract][Full Text] [Related]
8. Over-expression of urokinase receptor in human epidermoid-carcinoma cell line (HEp3) increases tumorigenicity on chorio-allantoic membrane and in severe-combined-immunodeficient mice.
Lyu MA; Choi YK; Park BN; Kim BJ; Park IK; Hyun BH; Kook YH
Int J Cancer; 1998 Jul; 77(2):257-63. PubMed ID: 9650562
[TBL] [Abstract][Full Text] [Related]
9. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS
Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219
[TBL] [Abstract][Full Text] [Related]
10. Quercetin Has Antimetastatic Effects on Gastric Cancer Cells via the Interruption of uPA/uPAR Function by Modulating NF-κb, PKC-δ, ERK1/2, and AMPKα.
Li H; Chen C
Integr Cancer Ther; 2018 Jun; 17(2):511-523. PubMed ID: 28627240
[TBL] [Abstract][Full Text] [Related]
11. [Relationship between urokinase-type plasminogen activator expression and peritoneal metastatic potency in different gastric cancer cell lines].
Ding YC; Zhu ZG; Liu BY; Ji YB; Chen XH; Zhang Y; Yu YY; Lin YZ
Zhonghua Wei Chang Wai Ke Za Zhi; 2005 May; 8(3):249-51. PubMed ID: 16167240
[TBL] [Abstract][Full Text] [Related]
12. P38 MAPK pathway is involved in the urokinase plasminogen activator expression in human gastric SNU-638 cells.
Shin BA; Yoo HG; Kim HS; Kim MH; Hwang YS; Chay KO; Lee KY; Ahn BW; Jung YD
Oncol Rep; 2003; 10(5):1467-71. PubMed ID: 12883725
[TBL] [Abstract][Full Text] [Related]
13. Expression of urokinase-type plasminogen activator, its receptor, and its inhibitor in gastric adenocarcinoma tissues.
Hong SI; Park IC; Son YS; Lee SH; Kim BG; Lee JI; Lee TW; Kook YH; Min YI; Hong WS
J Korean Med Sci; 1996 Feb; 11(1):33-7. PubMed ID: 8703368
[TBL] [Abstract][Full Text] [Related]
14. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
[TBL] [Abstract][Full Text] [Related]
15. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
[TBL] [Abstract][Full Text] [Related]
16. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
17. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model.
Frandsen TL; Holst-Hansen C; Nielsen BS; Christensen IJ; Nyengaard JR; Carmeliet P; Brünner N
Cancer Res; 2001 Jan; 61(2):532-7. PubMed ID: 11212246
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of urokinase-type plasminogen activator (uPA), its receptor (uPA-R), and inhibitor type-2 (PAI-2) during differentiation of keratinocytes in an organotypic coculture system.
Schaefer BM; Stark HJ; Fusenig NE; Todd RF; Kramer MD
Exp Cell Res; 1995 Oct; 220(2):415-23. PubMed ID: 7556451
[TBL] [Abstract][Full Text] [Related]
19. Stable transfection of urokinase-type plasminogen activator antisense construct modulates invasion of human glioblastoma cells.
Mohanam S; Jasti SL; Kondraganti SR; Chandrasekar N; Kin Y; Fuller GN; Lakka SS; Kyritsis AP; Dinh DH; Olivero WC; Gujrati M; Yung WK; Rao JS
Clin Cancer Res; 2001 Aug; 7(8):2519-26. PubMed ID: 11489835
[TBL] [Abstract][Full Text] [Related]
20. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Gnessi L; Catania A; Pellizzo MR; Nardi F; Mian C; De Antoni E; D'Armiento M; Frati L
J Clin Endocrinol Metab; 2011 Feb; 96(2):504-8. PubMed ID: 21106716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
